Phathom Pharmaceuticals (PHAT) Other Accumulated Expenses (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Other Accumulated Expenses for 8 consecutive years, with $6.9 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Other Accumulated Expenses rose 42.29% year-over-year to $6.9 million; the TTM figure through Jun 2026 stood at $6.9 million (up 42.29% YoY), while the FY2025 annual figure was $7.5 million, up 146.39% from the prior year.
• Other Accumulated Expenses climbed to $6.9 million in Q2 2026 per PHAT's latest filing, from $5.6 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $7.5 million in Q4 2025 and bottomed at $20000.0 in Q3 2023.
• Historically, Other Accumulated Expenses has averaged $2.2 million across 5 years, with a median of $811500.0 in 2024.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses slumped 46.15% — and 2024, when it jumped 8865.0%.
• Phathom Pharmaceuticals' Other Accumulated Expenses stood at $151000.0 in 2022, then declined by 22.52% to $117000.0 in 2023, then jumped by 2501.71% to $3.0 million in 2024, then soared by 146.39% to $7.5 million in 2025, then slipped by 7.59% to $6.9 million in 2026.
• Business Quant data shows PHAT's Other Accumulated Expenses at $6.9 million in Q2 2026, $5.6 million in Q1 2026, and $7.5 million in Q4 2025.